Search for: "Eli Lilly & Co."
Results 741 - 760
of 1,004
Sort by Relevance
|
Sort by Date
21 Nov 2009, 3:35 am
In April, the FDA sent warning letters to 14 companies, including Eli Lilly and Co and Merck & Co Inc., about their drug marketing online, saying that ads for certain products were misleading and did not contain any risk information. [read post]
19 Nov 2009, 9:59 pm
Eli Lilly & Co. [read post]
18 Nov 2009, 4:57 am
Eli Lilly & Co. [read post]
18 Nov 2009, 4:57 am
Eli Lilly & Co. [read post]
18 Nov 2009, 4:57 am
Eli Lilly & Co. [read post]
16 Nov 2009, 9:59 pm
Eli Lilly & Co., which is scheduled for December 7th. [read post]
12 Nov 2009, 9:17 am
Eli Lilly & Co., 66 Fed. [read post]
12 Nov 2009, 6:43 am
The AP reports, "Utah has agreed to a $24 million settlement with Eli Lilly & Co. over claims the drugmaker engaged in off-label marketing of the anti-psychotic drug Zyprexa [olanzapine]," according to Attorney General Mark Shurtleff. [read post]
10 Nov 2009, 9:59 pm
Eli Lilly & Co., which is scheduled for December 7th. [read post]
9 Nov 2009, 6:01 am
. $7 Billion in Penalties Since May 2004, Pfizer, Eli Lilly & Co., Bristol-Myers Squibb Co. and four other drug companies have paid a total of $7 billion in fines and penalties. [read post]
4 Nov 2009, 4:03 am
Stakeholders react to draft report (IP Watch) US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch) Products Ceclor (Cefaclor) – Canada: Eli Lilly successful in patent infringement action against Apotex (Pharmacapsules @ Gowlings) Oxytrol (Oxybutynin) – US: Watson and Barr settle… [read post]
4 Nov 2009, 4:03 am
Stakeholders react to draft report (IP Watch) US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch) Products Ceclor (Cefaclor) - Canada: Eli Lilly successful in patent infringement action against Apotex (Pharmacapsules @ Gowlings) Oxytrol (Oxybutynin) - US: Watson and Barr settle patent litigation (SmartBrief)… [read post]
4 Nov 2009, 4:03 am
Stakeholders react to draft report (IP Watch) US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch) Products Ceclor (Cefaclor) – Canada: Eli Lilly successful in patent infringement action against Apotex (Pharmacapsules @ Gowlings) Oxytrol (Oxybutynin) – US: Watson and Barr settle patent… [read post]
4 Nov 2009, 2:03 am
Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. [read post]
4 Nov 2009, 2:03 am
Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. [read post]
3 Nov 2009, 2:35 pm
For the drug-company perspective concerning this Byetta label change about kidney-related side effects, we direct you to the October 2009 "Dear Doctor" letter from Amylin Pharmaceuticals Inc. and Eli Lilly and Co. [read post]
2 Nov 2009, 11:04 pm
Amylin Pharmaceuticals Inc. and Eli Lilly & Co. said safety warnings were strengthened for their diabetes drug Byetta relating to the risks of pancreatitis and the medicine's use by patients with severe kidney disease. [read post]
25 Oct 2009, 10:18 am
Hasbro, Blackrock, Pfizer, Wells Fargo, Eli Lilly, Morgan Stanley, Deutsche Bank, Gannett, Merck, UPS, McDonald's, Microsoft, American Express, and Amazon, among others. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces settlement… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
